Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 561

1.

Vaccine against Middle East respiratory syndrome coronavirus.

Zumla A, Memish ZA, Hui DS, Perlman S.

Lancet Infect Dis. 2019 Oct;19(10):1054-1055. doi: 10.1016/S1473-3099(19)30477-3. No abstract available.

PMID:
31559955
2.

Urogenital tuberculosis - epidemiology, pathogenesis and clinical features.

Muneer A, Macrae B, Krishnamoorthy S, Zumla A.

Nat Rev Urol. 2019 Oct;16(10):573-598. doi: 10.1038/s41585-019-0228-9. Epub 2019 Sep 23. Review.

PMID:
31548730
3.

Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials.

Lanini S, Ioannidis JPA, Vairo F, Pletschette M, Portella G, Di Bari V, Mammone A, Pisapia R, Merler S, Nguhuni B, Langer M, Di Caro A, Edwards SJL, Petrosillo N, Zumla A, Ippolito G.

Lancet Infect Dis. 2019 Aug 23. pii: S1473-3099(19)30284-1. doi: 10.1016/S1473-3099(19)30284-1. [Epub ahead of print] Review.

PMID:
31451421
4.

Pulmonary Involvement during the Ebola Virus Disease.

Lalle E, Biava M, Nicastri E, Colavita F, Di Caro A, Vairo F, Lanini S, Castilletti C, Langer M, Zumla A, Kobinger G, Capobianchi MR, Ippolito G.

Viruses. 2019 Aug 24;11(9). pii: E780. doi: 10.3390/v11090780. Review.

5.

Risk of antibiotic resistant meningococcal infections in Hajj pilgrims.

Zumla A, Memish ZA.

BMJ. 2019 Aug 23;366:l5260. doi: 10.1136/bmj.l5260. No abstract available.

PMID:
31444169
6.

A One-Health lens for anthrax.

Kock R, Haider N, Mboera LE, Zumla A.

Lancet Planet Health. 2019 Jul;3(7):e285-e286. doi: 10.1016/S2542-5196(19)30111-1. No abstract available.

7.

Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study.

Lanini S, Bartolini B, Taibi C, Agresta A, Garbuglia AR, Montaldo C, Pisapia R, D'Offizi G, Scognamiglio P, Capobianchi MR, Zumla A, Ippolito G.

New Microbiol. 2019 Jul;42(3):139-144. Epub 2019 Jul 15.

8.

Confronting the persisting threat of the Middle East respiratory syndrome to global health security.

Perlman S, Azhar EI, Memish ZA, Hui DS, Zumla A.

Lancet Infect Dis. 2019 Jul 3. pii: S1473-3099(19)30347-0. doi: 10.1016/S1473-3099(19)30347-0. [Epub ahead of print] No abstract available.

PMID:
31279728
9.

High-income countries and latent tuberculosis infection screening for migrants - Authors' reply.

Petersen E, Chakaya J, Jawad FM, Ippolito G, Zumla A.

Lancet Infect Dis. 2019 Jul;19(7):691-692. doi: 10.1016/S1473-3099(19)30283-X. No abstract available.

PMID:
31250815
10.

Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed Therapies.

Rao M, Dodoo E, Zumla A, Maeurer M.

Front Microbiol. 2019 May 7;10:962. doi: 10.3389/fmicb.2019.00962. eCollection 2019. Review.

11.

Mass gatherings medicine: public health issues arising from mass gathering religious and sporting events.

Memish ZA, Steffen R, White P, Dar O, Azhar EI, Sharma A, Zumla A.

Lancet. 2019 May 18;393(10185):2073-2084. doi: 10.1016/S0140-6736(19)30501-X. Review.

PMID:
31106753
12.

Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention.

Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, Zumla A.

Infect Dis Clin North Am. 2019 Apr 10. pii: S0891-5520(19)30017-0. doi: 10.1016/j.idc.2019.03.001. [Epub ahead of print] Review.

PMID:
30981594
13.

Editorial: Toward improving the diagnosis, treatment and prevention of community acquired and nosocomial respiratory tract infections.

Niederman MS, Zumla A.

Curr Opin Pulm Med. 2019 May;25(3):217-219. doi: 10.1097/MCP.0000000000000577. No abstract available.

PMID:
30920457
14.

Recent advances in the development and evaluation of molecular diagnostics for Ebola virus disease.

Tembo J, Simulundu E, Changula K, Handley D, Gilbert M, Chilufya M, Asogun D, Ansumana R, Kapata N, Ntoumi F, Ippolito G, Zumla A, Bates M.

Expert Rev Mol Diagn. 2019 Apr;19(4):325-340. doi: 10.1080/14737159.2019.1595592. Epub 2019 Apr 5.

PMID:
30916590
15.

After the UNGA High-Level Meeting on Tuberculosis-what next and how?

Sahu S, Ditiu L, Zumla A.

Lancet Glob Health. 2019 May;7(5):e558-e560. doi: 10.1016/S2214-109X(19)30068-3. Epub 2019 Mar 12. No abstract available.

16.

Revolutionary new treatment regimens for multidrug-resistant tuberculosis.

McHugh TD, Honeyborne I, Lipman M, Zumla A.

Lancet Infect Dis. 2019 Mar;19(3):233-234. doi: 10.1016/S1473-3099(19)30060-X. No abstract available.

PMID:
30833051
17.

Latent tuberculosis infection: diagnostic tests and when to treat.

Petersen E, Chakaya J, Jawad FM, Ippolito G, Zumla A.

Lancet Infect Dis. 2019 Mar;19(3):231-233. doi: 10.1016/S1473-3099(19)30059-3. No abstract available.

PMID:
30833050
18.

Isoniazid preventive therapy for children in sub-Saharan Africa.

Meremikwu M, Zumla A.

Lancet Respir Med. 2019 Mar;7(3):197-199. doi: 10.1016/S2213-2600(19)30037-2. No abstract available.

PMID:
30823970
19.

Towards optimal treatment for latent Mycobacterium tuberculosis infection.

Abubakar I, Chakaya J, Maeurer M, Zumla A.

Lancet Respir Med. 2019 Mar;7(3):195-197. doi: 10.1016/S2213-2600(19)30036-0. No abstract available.

PMID:
30823969
20.

Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground.

Rao M, Ippolito G, Mfinanga S, Ntoumi F, Yeboah-Manu D, Vilaplana C, Zumla A, Maeurer M.

Int J Infect Dis. 2019 Mar;80S:S58-S61. doi: 10.1016/j.ijid.2019.02.035. Epub 2019 Feb 26.

21.

World Tuberculosis Day March 24th 2019 Theme: "It's TIME" - International Journal of Infectious Diseases Tuberculosis Theme Series.

Petersen E, Rao M, Ippolito G, Gualano G, Chakaya J, Ntoumi F, Moore D, Allen R, Gaskell K, Öhd JN, Hergens MP, Krishnamoorthy S, Ugarte-Gil C, Kirwan DE, Honeyborne I, McHugh TD, Köser CU, Kranzer K, Tiberi S, Migliori GB, Mao Q, Yang Y, Oliveira SP, Cardoso RF, Detjen A, Marais B, de Gijsel D, von Reyn CF, Goscé L, Abubakar I, Maeurer M, Zumla A.

Int J Infect Dis. 2019 Mar;80S:S1-S5. doi: 10.1016/j.ijid.2019.02.024. Epub 2019 Feb 23. No abstract available.

22.

The changing treatment landscape for MDR/XDR-TB - Can current clinical trials revolutionise and inform a brave new world?

Honeyborne I, Lipman M, Zumla A, McHugh TD.

Int J Infect Dis. 2019 Mar;80S:S23-S28. doi: 10.1016/j.ijid.2019.02.006. Epub 2019 Feb 15. No abstract available.

23.

Latent tuberculosis infection and renal transplantation - Diagnosis and management.

Krishnamoorthy S, Kumaresan N, Zumla A.

Int J Infect Dis. 2019 Mar;80S:S73-S76. doi: 10.1016/j.ijid.2019.01.049. Epub 2019 Feb 6.

24.

Tuberculin skin test - Outdated or still useful for Latent TB infection screening?

Gualano G, Mencarini P, Lauria FN, Palmieri F, Mfinanga S, Mwaba P, Chakaya J, Zumla A, Ippolito G.

Int J Infect Dis. 2019 Mar;80S:S20-S22. doi: 10.1016/j.ijid.2019.01.048. Epub 2019 Feb 6. Review.

25.

Transmission and prevention of acute viral respiratory tract infections in hospitals.

Wilson P, Zumla A.

Curr Opin Pulm Med. 2019 May;25(3):220-224. doi: 10.1097/MCP.0000000000000566.

PMID:
30730312
26.

Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future.

Rao M, Ippolito G, Mfinanga S, Ntoumi F, Yeboah-Manu D, Vilaplana C, Zumla A, Maeurer M.

Int J Infect Dis. 2019 Mar;80S:S62-S67. doi: 10.1016/j.ijid.2019.01.039. Epub 2019 Jan 24.

27.

RESPIRE: The National Institute for Health Research's (NIHR) Global Respiratory Health Unit.

Sheikh A, Campbell H, Balharry D, Baqui AH, Bogaert D, Cresswell K, Cunningham S, Dockerell D, El Arifeen S, Fletcher M, Grant L, Ghazali SS, Habib M, Hazir T, Isaac R, Juvekar S, Khoo EM, McKinstry B, Morris AD, Nair H, Norrie J, Nwaru BI, Pinnock H, Robertson D, Saha S, Salvi S, Schwarze J, Simpson C, Sridhar D, Stoddart A, Weller D, Whyte M, Worth A, Williams S, Yusuf O, Zumla A, Rudan I; RESPIRE Collaboration.

J Glob Health. 2018 Dec;8(2):020101. doi: 10.7189/jogh.08.020101. No abstract available.

28.

Improving access to multi-drug resistant tuberculosis diagnostic and health services for refugees and migrants.

Zumla A, Abubakar I.

BMC Med. 2018 Nov 30;16(1):221. doi: 10.1186/s12916-018-1218-0.

29.

Universal health coverage for refugees and migrants in the twenty-first century.

Abubakar I, Zumla A.

BMC Med. 2018 Nov 26;16(1):216. doi: 10.1186/s12916-018-1208-2.

30.

Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era.

Petersen E, Abubakar I, Ihekweazu C, Heymann D, Ntoumi F, Blumberg L, Asogun D, Mukonka V, Lule SA, Bates M, Honeyborne I, Mfinanga S, Mwaba P, Dar O, Vairo F, Mukhtar M, Kock R, McHugh TD, Ippolito G, Zumla A.

Int J Infect Dis. 2019 Jan;78:78-84. doi: 10.1016/j.ijid.2018.11.008. Epub 2018 Nov 16. Review.

31.

Achieving sustainable development goals for HIV/AIDS in the Republic of the Congo - Progress, obstacles and challenges in HIV/AIDS health services.

Ghoma Linguissi LS, Lucaccioni V, Bates M, Zumla A, Ntoumi F.

Int J Infect Dis. 2018 Dec;77:107-112. doi: 10.1016/j.ijid.2018.10.009. Epub 2018 Oct 17. Review.

32.

Advancing global tuberculosis control after the UNGA-HLM.

Marais B, Zumla A.

Lancet. 2018 Sep 29;392(10153):1096-1097. doi: 10.1016/S0140-6736(18)32361-4. Epub 2018 Sep 24. No abstract available.

PMID:
30262331
33.

The historic and unprecedented United Nations General Assembly High Level Meeting on Tuberculosis (UNGA-HLM-TB)-'United to End TB: An Urgent Global Response to a Global Epidemic'.

Zumla A, Petersen E.

Int J Infect Dis. 2018 Oct;75:118-120. doi: 10.1016/j.ijid.2018.09.017. Epub 2018 Sep 19. No abstract available.

34.

Effectiveness of service models and organisational structures supporting tuberculosis identification and management in hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review.

Heuvelings CC, Greve PF, de Vries SG, Visser BJ, Bélard S, Janssen S, Cremers AL, Spijker R, Shaw E, Hill RA, Zumla A, Sandgren A, van der Werf MJ, Grobusch MP.

BMJ Open. 2018 Sep 8;8(9):e019642. doi: 10.1136/bmjopen-2017-019642.

35.

Children infected by human herpesvirus 6B with febrile seizures are more likely to develop febrile status epilepticus: A case-control study in a referral hospital in Zambia.

Tembo J, Chandwe K, Kabwe M, Chilufya M, Ciccone O, Mpabalwani E, Ablashi D, Zumla A, Chen T, Bates M.

J Med Virol. 2018 Nov;90(11):1757-1764. doi: 10.1002/jmv.25269. Epub 2018 Aug 13.

PMID:
30011348
36.

Tuberculosis series.

Silva DR, Mello FCQ, Kritski A, Dalcolmo M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):71-72. doi: 10.1590/s1806-37562018000020001. English, Portuguese. No abstract available.

37.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. Review. Portuguese, English.

38.

Limiting consumption in tuberculosis: current concepts in anti-tuberculosis treatment in the critically ill patient.

Mer M, Zumla A, Dünser MW.

Intensive Care Med. 2018 Dec;44(12):2229-2231. doi: 10.1007/s00134-018-5161-5. Epub 2018 May 11. No abstract available.

PMID:
29752523
39.

Mitigating the risks of global spread of Lassa fever at the 2018 Hajj pilgrimage.

Gautret P, Okolo S, Elachola H, Zumla A, Memish ZA.

Travel Med Infect Dis. 2018 May - Jun;23:99-100. doi: 10.1016/j.tmaid.2018.04.016. Epub 2018 Apr 27. No abstract available.

PMID:
29709659
40.

Global spread of antibiotic-resistant bacteria and mass-gathering religious events.

Zumla A, Azhar EI, Hui DS, Shafi S, Petersen E, Memish ZA.

Lancet Infect Dis. 2018 May;18(5):488-490. doi: 10.1016/S1473-3099(18)30242-1. No abstract available.

PMID:
29695351
41.

Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission.

Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A.

Lancet Infect Dis. 2018 Aug;18(8):e217-e227. doi: 10.1016/S1473-3099(18)30127-0. Epub 2018 Apr 18. Review.

PMID:
29680581
42.

The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.

Floyd K, Glaziou P, Zumla A, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):299-314. doi: 10.1016/S2213-2600(18)30057-2. Review.

PMID:
29595511
43.

Tuberculosis research and development: seeding the future.

Lienhardt C, Zumla A, Gebreselassie N, Frick M, Gray G, Kasaeva T, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):242-244. doi: 10.1016/S2213-2600(18)30050-X. No abstract available.

PMID:
29595503
44.

B cells or T cells in TB: a continuing conundrum.

Maeurer M, Rao M, Zumla A.

Lancet Respir Med. 2018 Apr;6(4):237-238. doi: 10.1016/S2213-2600(18)30080-8. No abstract available.

PMID:
29595500
45.

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5. Epub 2018 Mar 23. Review. Erratum in: Lancet Infect Dis. 2018 Apr 27;:.

PMID:
29580819
46.

Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.

Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e199-e210. doi: 10.1016/S1473-3099(18)30111-7. Epub 2018 Mar 23. Review.

PMID:
29580818
47.

Concrete action now: UN High-Level Meeting on Tuberculosis.

Herbert N, Sharma V, Masham BS, Sheehan BS, Hauser J, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):709-710. doi: 10.1016/S1473-3099(18)30171-3. Epub 2018 Mar 23. No abstract available.

PMID:
29580817
48.

Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB".

Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-Manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, Rao M, Kapata N, Azhar EI, Memish ZA, Mfinanga S, Aseffa A, Ippolito G, Migliori GB, Zumla A.

Int J Infect Dis. 2018 Mar;68:122-124. doi: 10.1016/j.ijid.2018.03.002. Epub 2018 Mar 22. No abstract available.

49.

The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control.

Otu A, Hashmi M, Mukhtar AM, Kwizera A, Tiberi S, Macrae B, Zumla A, Dünser MW, Mer M.

J Crit Care. 2018 Jun;45:184-196. doi: 10.1016/j.jcrc.2018.03.015. Epub 2018 Mar 13. Review.

PMID:
29571116
50.

Accelerating the development of therapeutic strategies for drug-resistant tuberculosis.

Vjecha MJ, Tiberi S, Zumla A.

Nat Rev Drug Discov. 2018 Sep;17(9):607-608. doi: 10.1038/nrd.2018.28. Epub 2018 Mar 23.

PMID:
29567994

Supplemental Content

Support Center